Literature DB >> 2672242

Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain.

C Montalban1, R Martinez-Fernandez, J L Calleja, J D Garcia-Diaz, R Rubio, F Dronda, S Moreno, M Yebra, C Barros, J Cobo.   

Abstract

In an area endemic for visceral leishmaniasis, 16 patients with human immunodeficiency virus (HIV) infection developed the disease. All belonged to populations at risk for AIDS (15 were intravenous drug abusers). Five patients fulfilled the criteria for full-blown AIDS, and two more fulfilled them after diagnosis of leishmaniasis. All presented with the classic manifestations of visceral leishmaniasis, but leishmania serology was negative in 15 patients (93%). Leishmania donovani amastigotes were identified in the bone marrow in all cases. Most patients responded initially to treatment with pentavalent antimonial drugs, but seven (43%) followed a chronic course, with multiple relapses in five, despite alternative treatments. Visceral leishmaniasis occurred in patients with different levels of depression of the CD4 to CD8 lymphocyte ratio. Mortality was 37% (six patients) and was independent of the chronic-relapsing course of the disease. In no case was leishmaniasis the primary cause of death. Our data establish that visceral leishmaniasis is an opportunistic infection in HIV-infected patients, and we suggest that in endemic areas it should be considered an indicator disease for the diagnosis of AIDS.

Entities:  

Mesh:

Year:  1989        PMID: 2672242     DOI: 10.1093/clinids/11.4.655

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

1.  Pleural and peritoneal leishmaniasis in an AIDS patient.

Authors:  F J Muñoz-Rodríguez; S Padró; P Pastor; D Rosa-Re; M E Valls; J M Miró; J M Gatell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma.

Authors:  D E Wyatt; P V Coyle
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

3.  Visceral leishmaniasis in human immunodeficiency virus disease.

Authors:  C Montalban
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.

Authors:  S S Kashino; C Abeijon; L Qin; K A Kanunfre; F S Kubrusly; F O Silva; D L Costa; D Campos; C H N Costa; I Raw; A Campos-Neto
Journal:  Parasite Immunol       Date:  2012-07       Impact factor: 2.280

5.  Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment.

Authors:  S Fenske; H J Stellbrink; H Albrecht; H Greten
Journal:  Klin Wochenschr       Date:  1991-10-31

6.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

7.  Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

Authors:  F Lozano; J Torre-Cisneros; A Bascuñana; J Polo; P Viciana; M A García-Ordóñez; J Hernández-Quero; M Márquez; A Vergara; F Díez; E Pujol; M Torres-Tortosa; J Pasquau; J J Hernández-Burruezo; I Suárez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

Review 8.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

9.  In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma.

Authors:  C L Karp; S H el-Safi; T A Wynn; M M Satti; A M Kordofani; F A Hashim; M Hag-Ali; F A Neva; T B Nutman; D L Sacks
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.